KR20230107568A - 섬유증 치료 방법 - Google Patents

섬유증 치료 방법 Download PDF

Info

Publication number
KR20230107568A
KR20230107568A KR1020237015750A KR20237015750A KR20230107568A KR 20230107568 A KR20230107568 A KR 20230107568A KR 1020237015750 A KR1020237015750 A KR 1020237015750A KR 20237015750 A KR20237015750 A KR 20237015750A KR 20230107568 A KR20230107568 A KR 20230107568A
Authority
KR
South Korea
Prior art keywords
fibrosis
hydrogen
gli1
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015750A
Other languages
English (en)
Korean (ko)
Inventor
로스 리오스 미구엘 데
존 후드
아니타 디프란체스코
Original Assignee
엔데버 바이오메디신스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔데버 바이오메디신스, 인크. filed Critical 엔데버 바이오메디신스, 인크.
Publication of KR20230107568A publication Critical patent/KR20230107568A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237015750A 2020-10-13 2021-10-13 섬유증 치료 방법 Pending KR20230107568A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (1)

Publication Number Publication Date
KR20230107568A true KR20230107568A (ko) 2023-07-17

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015750A Pending KR20230107568A (ko) 2020-10-13 2021-10-13 섬유증 치료 방법

Country Status (8)

Country Link
US (4) US11628167B2 (cg-RX-API-DMAC7.html)
EP (1) EP4229828A4 (cg-RX-API-DMAC7.html)
JP (2) JP7868066B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230107568A (cg-RX-API-DMAC7.html)
CN (1) CN116349204A (cg-RX-API-DMAC7.html)
AU (1) AU2021360767A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198661A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022081661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
CN120916760A (zh) * 2023-02-28 2025-11-07 奋进生物医药公司 治疗纤维化的方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (cg-RX-API-DMAC7.html) 1977-06-03 1981-03-07 Pfizer
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2011088404A1 (en) 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9970935B2 (en) * 2014-02-06 2018-05-15 The Brigham And Women's Hospital, Inc. Uses of GLI1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
EP3383912A4 (en) 2015-11-30 2019-11-06 Ignyta, Inc. TOPICAL FORMULATIONS
US20190255042A1 (en) * 2016-11-04 2019-08-22 Impact Therapeutics, Inc Application of hedgehog pathway inhibitor in treating fibrosis diseases
US11154541B2 (en) 2018-06-29 2021-10-26 The Trustees Of Indiana University Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor
CN112449602A (zh) * 2018-07-19 2021-03-05 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN120916760A (zh) 2023-02-28 2025-11-07 奋进生物医药公司 治疗纤维化的方法

Also Published As

Publication number Publication date
US20220265650A1 (en) 2022-08-25
US11628167B2 (en) 2023-04-18
JP7868066B2 (ja) 2026-06-01
US20240342170A1 (en) 2024-10-17
WO2022081661A1 (en) 2022-04-21
US12295954B2 (en) 2025-05-13
AU2021360767A1 (en) 2023-04-27
US12213974B2 (en) 2025-02-04
JP2023546536A (ja) 2023-11-02
US20250235452A1 (en) 2025-07-24
EP4229828A1 (en) 2023-08-23
JP2026124900A (ja) 2026-07-31
EP4229828A4 (en) 2024-08-28
CA3198661A1 (en) 2022-04-21
CN116349204A (zh) 2023-06-27
US20230201195A1 (en) 2023-06-29
AU2021360767A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US11628167B2 (en) Method of treating fibrosis
US12605377B2 (en) Methods of treating fibrosis
JP6170040B2 (ja) ピルフェニドン及び選択された患者における抗線維化療法
AU2020407882A1 (en) Treatment of amyotrophic lateral sclerosis and related disorders
KR20250162569A (ko) 섬유증 치료 방법
JP2018501217A (ja) 統合失調症を治療するための2−((1−(2(4−フルオロフェニル)−2−オキソエチル)ピペリジン−4−イル)メチル)イソインドリン−1−オン
JP6621534B2 (ja) 慢性咳の処置のためのオルブピタント
JPWO2019160057A1 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2025271047A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
Kerstjens et al. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients
KR20260004530A (ko) 진행성 섬유화 간질성 폐 질환의 치료를 위한 신규한 경구 약제학적 조성물 및 투여 섭생
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのmGluR5アンタゴニストの使用
US20200368246A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
JP6454436B1 (ja) ペマフィブラートを含有する医薬
CN120265291A (zh) 喹唑啉酮化合物的新用途和制剂
CN118302167A (zh) 用于治疗进行性纤维化间质性肺病的新颖口服药物组合物及剂量方案
CA2753754C (en) Methods for treating schizophrenia
CN118369098A (zh) 用于治疗进行性纤维化间质性肺病的新颖治疗组合
JP2005531622A5 (cg-RX-API-DMAC7.html)
Cole American Academy of Neurology 64th Annual Meeting, New Orleans, Louisiana, USA-April 21-28, 2012

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241011

Comment text: Request for Examination of Application